With respect to 5-FU treatment, it has been described that CRC patients with APC mutations do not benefit from 5-FU therapy [30], possibly due to interaction of 5-FU with the APC DNA repair inhibitory domain [31]. The gene discussed is APC; the disease is colorectal carcinoma.